Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaofei Jiao

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 5, 2025
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancerShen-Nan Shi, Qiuyang Xu, Zhiqi Liao, et al.
Journal of Ovarian Research|June 27, 2023
Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world studyXingyu Liu, Yingjun Zhao, Xiaofei Jiao, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|December 9, 2022
Does the primary treatment sequence affect post-relapse survival in recurrent epithelial ovarian cancer? A real-world multicentre retrospective studyXingyu Liu, Yingjun Zhao, Xiaofei Jiao, et al.
Journal of Ovarian Research|February 18, 2025
The impact of preoperative immunonutritional status on prognosis in ovarian cancer: a multicenter real-world studyXingyu Liu, Ming Li, Yingjun Zhao, et al.
Journal of Ovarian Research|April 29, 2025
The impact of preoperative immunonutritional status on postoperative complications in ovarian cancerXingyu Liu, Ming Li, Yingjun Zhao, et al.
Eclinicalmedicine|August 26, 2020
Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort studyDan Liu, Pengfei Cui, Shaoqing Zeng, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|December 9, 2022
The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective studyShaoqing Zeng, Jianhua Chi, Jiahao Liu, et al.
Cell|July 6, 2024
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsYikai Luo, Yu Xia, Dan Liu, et al.
Med (New York, N.Y.)|January 19, 2025
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trialHuayi Li, Yu Xu, Xiaofei Jiao, et al.
The Lancet. Digital Health|February 26, 2022
Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic studyYue Gao, Shaoqing Zeng, Xiaoyan Xu, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|November 5, 2025
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancerShen-Nan Shi, Qiuyang Xu, Zhiqi Liao, et al.
Journal of Ovarian Research|June 27, 2023
Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world studyXingyu Liu, Yingjun Zhao, Xiaofei Jiao, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|December 9, 2022
Does the primary treatment sequence affect post-relapse survival in recurrent epithelial ovarian cancer? A real-world multicentre retrospective studyXingyu Liu, Yingjun Zhao, Xiaofei Jiao, et al.
Journal of Ovarian Research|February 18, 2025
The impact of preoperative immunonutritional status on prognosis in ovarian cancer: a multicenter real-world studyXingyu Liu, Ming Li, Yingjun Zhao, et al.
Journal of Ovarian Research|April 29, 2025
The impact of preoperative immunonutritional status on postoperative complications in ovarian cancerXingyu Liu, Ming Li, Yingjun Zhao, et al.
Eclinicalmedicine|August 26, 2020
Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort studyDan Liu, Pengfei Cui, Shaoqing Zeng, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|December 9, 2022
The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective studyShaoqing Zeng, Jianhua Chi, Jiahao Liu, et al.
Cell|July 6, 2024
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumorsYikai Luo, Yu Xia, Dan Liu, et al.
Med (New York, N.Y.)|January 19, 2025
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trialHuayi Li, Yu Xu, Xiaofei Jiao, et al.
The Lancet. Digital Health|February 26, 2022
Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic studyYue Gao, Shaoqing Zeng, Xiaoyan Xu, et al.
Pageof 4